#

Dailypharm Korea will be available without login access until the end of December 2019.
Membership login access would be required from February 2020 to access more news and website services.
Dailypharm Live Search Close
  • [Reporter’s View] COVID-19 and vaccine self-sufficiency
  • by An, Kyung-Jin | translator Byun Kyung A | May 18, 2020 06:15am
The U.S. and Europe have sparked a conflict over COVID-19 vaccine still in development. The tension arose when a multinational pharmaceutical company Sanofi announced its intention to prioritize the distribution of the vaccine to the U.S., in case the company successfully completes the development.

During an interview with Bloomberg, Sanofi’s British CEO Paul Hudson who newly took over the office in last September said, “The U.S. government has the right to the largest pre-order because it’s invested in taking the risk,” so “the Americans will likely get Sanofi’s COVID-19 vaccine before the rest of the world.” Along with its competitor GlaxoSmithKline (GSK), the French-based multinational company has initiated COVID-19 vaccine co-development project. And apparently, the U.S. Biomedical Advanced Research and Development Authority (BARDA) has provided USD 30 million (approximately 36.8 billion won) for the project

Immediately after the news was released, the whole of Europe was shaken. Particularly, the reaction from France, where Sanofi’s headquarters and manufacturing plants are housed, was rough. The French government was infuriated by the pharmaceutical company’s public comment as the country and the EU have been often giving direct and indirect support for the company’s R&D programs. French Prime Minister Édouard Philippe reproached by twitting “A #COVID19 vaccine should be a global public good. And the equal access to the vaccine is not negotiable.” The European Commission official also published a statement insisting that “The vaccine against COVID-19 should be a global public good and its access needs to be equitable and universal.”

The pharmaceutical industry experts are claiming the international cooperation has worsened as the EU intervened the U.S. and China’s race for the COVID-19 vaccine. Some are concerned that a war on exclusive pre-ordering of the vaccine in development may break out.

Eventually, CEO Hudson took back his words, as his ‘America-first’ comment has inflicted a firestorm. When the vaccine is fully developed, he said all countries around the world would have an equal access to the vaccine. But the CEO also urged “the European countries should also assertively take risks on the vaccine development like the U.S.” He pointed out how the U.S. is taking a risk even before scientifically confirming the success of the vaccine development, whereas the European countries have not. The CEO also argued the risk should be shared among European countries and the U.S.

Sanofi CEO’s comment also rings in a grave tone in Korea as well, where the country has not yet fully resolved the vaccine self-sufficiency issue. When Green Cross established the Hwasun vaccine plant in 2009, South Korea has become the 12th country in the world to locally procure flu vaccine. The locally made vaccine is viewed as the top contributor in overcoming the 2010 flu pandemic. Although it has been a decade since then, Korea’s self-sufficiency rate in vaccine has not improved much.

Out of 19 National Immunization Program (NIP) vaccine types, only six types—hepatitis B virus, hemorrhagic fever with renal syndrome (HFRS), varicella, influenza, tetanus, diphtheria, and pertussis (Td), Haemophilus influenzae type b (Hib)—are locally produced without importing the vaccine strain. Other three vaccine types are locally produced with imported strain, and the rest of the nine types are imported as finished products. In case of a pandemic or biologic terrorism, Korea has to unavoidably rely on other countries for vaccine. When the country cannot even self-procure vaccines long demanded, it is skeptical if Korea would be able to promptly produce vaccine during a novel infectious disease outbreak.

According to the World Health Organization’s (WHO) update, total eight cases of clinical studies in COVID-19 vaccine have started their global trial phase. Four of them are funded by Chinese government and corporations. Partnered with a biotechnology company Moderna, the U.S. National Institute of Allergy and Infectious Diseases (NIAID), associated under the National Institute of Health (NIH), has started a clinical trial for a vaccine against COVID-19 from last month. The U.S. government body aims to report the immunological reaction in around coming July or August.

In Korea, a number of pharmaceutical companies like SK Bioscience, GC Pharma and Genexine are seeking for a vaccine against COVID-19, but the progress is far behind compared to the U.S. or China. The country was able to put the limelight on its promising global level biotechnology as the world highly evaluated Korea’s ability to test the disease. To maintain the outstanding disease control capacity, the Korean government would need to invest and support the vaccine and treatment development, bottomlessly. Korea should let the latest pandemic be the reminder of the necessity of ‘vaccine self-sufficiency.’
  • 0
Reader Comment
0
Anonymity comment Write Operate Rule
Colse

댓글 운영방식은

댓글은 실명게재와 익명게재 방식이 있으며, 실명은 이름과 아이디가 노출됩니다. 익명은 필명으로 등록 가능하며, 대댓글은 익명으로 등록 가능합니다.

댓글 노출방식은

댓글 명예자문위원(팜-코니언-필기모양 아이콘)으로 위촉된 데일리팜 회원의 댓글은 ‘게시판형 보기’와 ’펼쳐보기형’ 리스트에서 항상 최상단에 노출됩니다. 새로운 댓글을 올리는 일반회원은 ‘게시판형’과 ‘펼쳐보기형’ 모두 팜코니언 회원이 쓴 댓글의 하단에 실시간 노출됩니다.

댓글의 삭제 기준은

다음의 경우 사전 통보없이 삭제하고 아이디 이용정지 또는 영구 가입제한이 될 수도 있습니다.

  • 저작권·인격권 등 타인의 권리를 침해하는 경우

    상용 프로그램의 등록과 게재, 배포를 안내하는 게시물

    타인 또는 제3자의 저작권 및 기타 권리를 침해한 내용을 담은 게시물

  • 근거 없는 비방·명예를 훼손하는 게시물

    특정 이용자 및 개인에 대한 인신 공격적인 내용의 글 및 직접적인 욕설이 사용된 경우

    특정 지역 및 종교간의 감정대립을 조장하는 내용

    사실 확인이 안된 소문을 유포 시키는 경우

    욕설과 비어, 속어를 담은 내용

    정당법 및 공직선거법, 관계 법령에 저촉되는 경우(선관위 요청 시 즉시 삭제)

    특정 지역이나 단체를 비하하는 경우

    특정인의 명예를 훼손하여 해당인이 삭제를 요청하는 경우

    특정인의 개인정보(주민등록번호, 전화, 상세주소 등)를 무단으로 게시하는 경우

    타인의 ID 혹은 닉네임을 도용하는 경우

  • 게시판 특성상 제한되는 내용

    서비스 주제와 맞지 않는 내용의 글을 게재한 경우

    동일 내용의 연속 게재 및 여러 기사에 중복 게재한 경우

    부분적으로 변경하여 반복 게재하는 경우도 포함

    제목과 관련 없는 내용의 게시물, 제목과 본문이 무관한 경우

    돈벌기 및 직·간접 상업적 목적의 내용이 포함된 게시물

    게시물 읽기 유도 등을 위해 내용과 무관한 제목을 사용한 경우

  • 수사기관 등의 공식적인 요청이 있는 경우

  • 기타사항

    각 서비스의 필요성에 따라 미리 공지한 경우

    기타 법률에 저촉되는 정보 게재를 목적으로 할 경우

    기타 원만한 운영을 위해 운영자가 필요하다고 판단되는 내용

  • 사실 관계 확인 후 삭제

    저작권자로부터 허락받지 않은 내용을 무단 게재, 복제, 배포하는 경우

    타인의 초상권을 침해하거나 개인정보를 유출하는 경우

    당사에 제공한 이용자의 정보가 허위인 경우 (타인의 ID, 비밀번호 도용 등)

  • ※이상의 내용중 일부 사항에 적용될 경우 이용약관 및 관련 법률에 의해 제재를 받으실 수도 있으며, 민·형사상 처벌을 받을 수도 있습니다.

    ※위에 명시되지 않은 내용이더라도 불법적인 내용으로 판단되거나 데일리팜 서비스에 바람직하지 않다고 판단되는 경우는 선 조치 이후 본 관리 기준을 수정 공시하겠습니다.

    ※기타 문의 사항은 데일리팜 운영자에게 연락주십시오. 메일 주소는 dailypharm@dailypharm.com입니다.

Write
Write
recently Agree DisAgree
If you want to see the full article, please JOIN US (click)